Distribution of serum zinc levels and supplementary effect of zinc acetate in chronic kidney disease (CKD) and hemodialysis (HD) patients.

Distribution of serum zinc levels and supplementary effect of zinc acetate in chronic kidney disease (CKD) and hemodialysis (HD) patients. - Prevalence of hypozincemia and effect of zinc in CKD and HD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029944

Enrollment

300

Registered

2017-11-14

Start date

2017-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD and HD patients CKD and HD patients with hypozincemia

Interventions

Daily oral administration of zinc acetate (NOBELZIN, 25-50 mg/time, b.i.d. or t.i.d. for a few months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD and HD patients diagnosed as zinc deficiency (serum zinc level < 60 micro g/dL) or latent zinc deficiency (60-80 micro g/dL)

Exclusion criteria

Exclusion criteria: 1. Patients without informed consent 2. Patients with poor drug adherence 3. Patients judged inappropriate by physicians

Design outcomes

Primary

Measure	Time frame
Serum zinc levels at baseline and at a few months after the zinc acetate-treatment started in the patients diagnosed as hypozincemia	—

Secondary

Measure	Time frame
1. Other serum chemistries 2. Questionnaire for clinical symptoms (only in zinc acetate-prescribed patients) 3. Prescription of other drugs	—

Countries

Japan

Contacts

Public ContactNobuo Nagano

Hidaka Hospital, Hidaka-kai Kidney Disease and Dialysis Center

n_nagano@hidaka-kai.com027-362-6201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026